The report on Blood Cancer Drugs Market by product (rituaxan/mabthera, gleevac/glivec, revlimid, velcade,
tasigna, pomalyst, vidaza, kyprolis, adcetris, and others) trends analysis and forecasts up to 2023 studies the
market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-
Pacific, Rest of the World. According to the report the Global Blood Cancer Drugs Market is projected to grow
at a CAGR between 10.5% to 11.5% in terms of value over the period of 2017-2023. The growth in the world
market is primarily driven by significant contribution by North America (Leading region) region to this market.
Get Sample Copy of this Report:-
https://www.infiniumglobalresearch.com/Reports/MakeSampleRequest/20
The higher costs of blood cancer drugs and therapies and the lack of supportive reimbursement policies and
insurance coverage for blood cancer therapies in many regions are the major restraints for the global blood
cancer drugs market. Biosimilars of biological drugs and generics of chemical drugs for cancer is expected to
provide opportunity for pharmaceutical companies to expand in the developing and least developed
countries, where the high costs of traditional blood cancer drugs are unaffordable for patients, during the
forecast period. Providing cost effective blood cancer drugs to the patients will be a major challenge for the
major pharmaceutical companies, due to the high investments required for research and development and
manufacturing, during the forecast period.
Segments Covered:
The report segments the global blood cancer drugs market by product and region. On the basis of product,
the market is segmented as rituaxan/mabthera, gleevac/glivec, revlimid, velcade, tasigna, pomalyst, vidaza,
kyprolis, adcetris, and others.
Infinium Global Research